Unión Europea - neerlandés - EMA (European Medicines Agency)

sanofi b.v. - avalglucosidase alfa - glycogeen opslag ziekte type ii - andere maagdarmkanaal en metabolisme producten, - nexviadyme (avalglucosidase alfa) is indicated for long-term enzyme replacement therapy for the treatment of patients with pompe disease (acid α-glucosidase deficiency).

Unión Europea - neerlandés - EMA (European Medicines Agency)

amicus therapeutics europe limited - cipaglucosidase alfa - glycogeen opslag ziekte type ii - andere maagdarmkanaal en metabolisme producten, - pombiliti (cipaglucosidase alfa) is a long-term enzyme replacement therapy used in combination with the enzyme stabiliser miglustat for the treatment of adults with late-onset pompe disease (acid α-glucosidase [gaa] deficiency).

Bélgica - neerlandés - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

b. braun melsungen ag - calciumgluconaat 94 mg/ml - eq. calcium 0,23 mmol/ml - oplossing voor injectie - calciumgluconaat 94 mg/ml - electrolytes

Países Bajos - neerlandés - myHealthbox

bayer ag - waterige oplossing - 480 g/l glyfosaat

Países Bajos - neerlandés - myHealthbox

bayer ag - waterige oplossing - 500 g/l glyfosaat

Países Bajos - neerlandés - myHealthbox

bayer ag - waterige oplossing - 450 g/l glyfosaat

Países Bajos - neerlandés - myHealthbox

bayer ag - vloeistof - 360 g/l glyfosaat

Países Bajos - neerlandés - myHealthbox

bayer ag - waterige oplossing - 360 g/l glyfosaat

Países Bajos - neerlandés - myHealthbox

bayer ag - waterige oplossing - 360 g/l glyfosaat

Unión Europea - neerlandés - EMA (European Medicines Agency)

amicus therapeutics europe limited - miglustat - glycogeen opslag ziekte type ii - andere voedings- en metabolismeproducten - opfolda (miglustat) is an enzyme stabiliser of cipaglucosidase alfa long-term enzyme replacement therapy in adults with late-onset pompe disease (acid α- glucosidase [gaa] deficiency).